{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:26:01Z","timestamp":1760189161070},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:00:00Z","timestamp":1281398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10549-010-1102-x","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T05:30:17Z","timestamp":1281331817000},"page":"837-842","source":"Crossref","is-referenced-by-count":16,"title":["Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy"],"prefix":"10.1007","volume":"123","author":[{"given":"Phuong K.","family":"Morrow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Divers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiuh-Wen","family":"Luoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa M.","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Giurescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schmelter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda T.","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,10]]},"reference":[{"key":"1102_CR1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137\u20132150. doi: 10.1200\/JCO.2005.05.2308","journal-title":"J Clin Oncol"},{"key":"1102_CR2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.11859","volume":"100","author":"SH Giordano","year":"2004","unstructured":"Giordano SH, Buzdar AU, Smith TL, Kau S-W, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44\u201352. doi: 10.1002\/cncr.11859","journal-title":"Cancer"},{"key":"1102_CR3","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","volume":"25","author":"ES Thomas","year":"2007","unstructured":"Thomas ES, Gomez HL, Li RK, Chung H-C, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roch\u00e9 HH (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210\u20135217. doi: 10.1200\/JCO.2007.12.6557","journal-title":"J Clin Oncol"},{"key":"1102_CR4","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","volume":"25","author":"EA Perez","year":"2007","unstructured":"Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN (2007) Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407\u20133414. doi: 10.1200\/JCO.2006.09.3849","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"1102_CR5","doi-asserted-by":"crossref","first-page":"v16","DOI":"10.1093\/annonc\/mdm174","volume":"18","author":"MN Fornier","year":"2007","unstructured":"Fornier MN (2007) Epothilones in breast cancer: review of clinical experience. Ann Oncol 18(Suppl 5):v16\u2013v21. doi: 10.1093\/annonc\/mdm174","journal-title":"Ann Oncol"},{"key":"1102_CR6","first-page":"115","volume":"7","author":"PG Morris","year":"2009","unstructured":"Morris PG, Fornier MN (2009) Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer. Clin Adv Hematol Oncol 7:115\u2013122","journal-title":"Clin Adv Hematol Oncol"},{"key":"1102_CR7","first-page":"523","volume":"33","author":"N Egerton","year":"2008","unstructured":"Egerton N (2008) Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer. P T 33:523\u2013531","journal-title":"P T"},{"key":"1102_CR8","doi-asserted-by":"crossref","unstructured":"Toppmeyer DL, Goodin S (2009) Ixabepilone, a new treatment option for metastatic breast cancer. Am J Clin Oncol (In press). doi: 10.1097\/COC.0b013e3181b9cd52","DOI":"10.1097\/COC.0b013e3181b9cd52"},{"key":"1102_CR9","first-page":"789","volume":"2","author":"KL Cheng","year":"2008","unstructured":"Cheng KL, Bradley T, Budman DR (2008) Novel microtubule-targeting agents\u2014the epothilones. Biologics 2:789\u2013811","journal-title":"Biologics"},{"key":"1102_CR10","unstructured":"Hoffman J, Fichtner I, Klar U (2006) ZK-EPO, a potent third generation epothilone, is effective in models of breast cancer metastasis. Presented at AACR; abstract 511"},{"key":"1102_CR11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/annonc\/mdp491","volume":"21","author":"P Schmid","year":"2010","unstructured":"Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, K\u00fchnhardt D (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21:633\u2013639. doi: 10.1093\/annonc\/mdp491","journal-title":"Ann Oncol"},{"key":"1102_CR12","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1200\/JCO.1999.17.7.2069","volume":"17","author":"PA Vasey","year":"1999","unstructured":"Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RPH, Atkinson R, Graham J, Crawford SM, Coleman R, Thomas H, Davis J, Eggleton SP, Kaye SB, for the Scottish Gynaecological Cancer Trials Group (1999) Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 17:2069\u20132080","journal-title":"J Clin Oncol"},{"key":"1102_CR13","unstructured":"National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"1102_CR14","unstructured":"Beer T, Smith DC, Hussain A, Alonso M, Neerukonda L, Hauke R, Wang Y, Giurescu M (2008) Phase II study of first-line sagopilone combined with prednisone in patients with metastatic androgen-independent prostate cancer (AIPC). Ann Oncol 19(Suppl 8):viii198, abstract 616P"},{"key":"1102_CR15","doi-asserted-by":"crossref","unstructured":"Daud A, Weber J, Urbas P, Andrews S, Maker N, Sondak VK, DeConti RC (2009) Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma. J Clin Oncol (Meet Abstr) 27: abstract 9031","DOI":"10.1200\/jco.2009.27.15_suppl.9031"},{"key":"1102_CR16","unstructured":"McMeekin S, Patel R, Verschraegen C, Celano P, Burke J, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y (2008) Phase I\/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Ann Oncol 19(Suppl 8):viii211, abstract 665O"},{"key":"1102_CR17","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1200\/JCO.2005.03.0981","volume":"23","author":"EH Rubin","year":"2005","unstructured":"Rubin EH, Rothermel J, Tesfaye F, Chen T, Hubert M, Ho Y-Y, Hsu C-H, Oza AM (2005) Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23:9120\u20139129. doi: 10.1200\/JCO.2005.03.0981","journal-title":"J Clin Oncol"},{"key":"1102_CR18","doi-asserted-by":"crossref","unstructured":"Low JA, Wedam SB, Brufsky A, Berman A, Croarkin E, Parks R, Steinberg SM, Mannan N, Fojo T, Swain SM (2004) A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily\u00a0\u00d7\u00a05 in breast cancer. J Clin Oncol 22: abstract 545","DOI":"10.1200\/jco.2004.22.90140.545"},{"key":"1102_CR19","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","volume":"25","author":"E Thomas","year":"2007","unstructured":"Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399\u20133406. doi: 10.1200\/JCO.2006.08.9102","journal-title":"J Clin Oncol"},{"key":"1102_CR20","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.ejca.2005.04.028","volume":"41","author":"G Bianchi","year":"2005","unstructured":"Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746\u20131750. doi: 10.1016\/j.ejca.2005.04.028","journal-title":"Eur J Cancer"},{"key":"1102_CR21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh078","volume":"127","author":"MS Wang","year":"2004","unstructured":"Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD (2004) Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 127:671\u2013679. doi: 10.1093\/brain\/awh078","journal-title":"Brain"},{"key":"1102_CR22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clon.2004.11.014","volume":"17","author":"MD Stubblefield","year":"2005","unstructured":"Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL (2005) Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 17:271\u2013276","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1102-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1102-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T17:55:00Z","timestamp":1685728500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1102-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,10]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1102-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,10]]}}}